Vivos Therapeutics, Inc. (VVOS) earnings
VVOS earnings moved a median of -2.88% by the close. Quarterly and annual VVOS reports and results, each read against the price at its own news timestamp. Back to the VVOS overview →
34 measured VVOS earnings events.
Where these VVOS earnings landedvs 31 measured VVOS earnings reactions
| Middle 50% of VVOS earnings reactions | -8.29% to +0.45% |
|---|---|
| Median reaction (to close) | -2.88% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 VVOS earnings events with a measured close landed between -8.29% and +0.45%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Vivos Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +6.31% | +0.07% | |
| Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update | Press release | +6.31% | +0.07% | |
| Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call | Press release | -0.58% | +11.71% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.37% | +0.83% | |
| Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update | Press release | +1.37% | +0.83% | |
| Form NT 10-Q Vivos Therapeutics, Inc. For: Mar 31 | SEC filing · Form NT | -1.57% | -6.70% | |
| Form 10-K Vivos Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.42% | -12.10% | |
| Form NT 10-K Vivos Therapeutics, Inc. For: Dec 31 | SEC filing · Form NT | -1.71% | +11.11% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +3.54% | -6.20% | |
| Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 | Press release | +3.54% | -6.20% | |
| Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call | Press release | +1.87% | -2.08% | |
| Form NT 10-Q Vivos Therapeutics, Inc. For: Sep 30 | SEC filing · Form NT | -0.84% | +0.00% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.07% | — | |
| Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update | Press release | +2.07% | — | |
| Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call | Press release | +1.92% | — | |
| Form NT 10-Q Vivos Therapeutics, Inc. For: Jun 30 | SEC filing · Form NT | -6.92% | -5.08% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.72% | -12.41% | |
| Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update | Press release | -1.72% | -12.41% | |
| Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call | Press release | +0.32% | -2.88% | |
| Form 10-K Vivos Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.48% | -6.74% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.13% | -9.84% | |
| Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update | Press release | -4.13% | -9.84% | |
| Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call | Press release | -1.92% | +0.00% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | -15.46% | |
| Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update | Press release | — | -15.46% | |
| Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call | Press release | — | +1.28% | |
| Form 10-K/A Vivos Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.29% | -6.03% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.70% | +2.35% | |
| Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update | Press release | -0.70% | +2.35% | |
| Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call | Press release | +3.96% | +23.27% | |
| Form 10-K Vivos Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.67% | -10.13% | |
| Form 10-Q Vivos Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.06% | -2.53% | |
| Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update | Press release | -0.06% | -2.53% | |
| Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call | Press release | +0.00% | -5.84% |
Keep exploring
More VVOS: analyst actions → · SEC filings → · VVOS overview →